NASDAQ: AZRX
SEARCH
SIGN UP
About
Back
Company Profile
Management Team
Board of Directors
Scientific Advisory Board
Science & Technology
Back
Products
Back
MS-1819
FW-420
FW-1022
Programs
Back
Pipeline
Clinical Trials
Back
Ongoing Clinical Trials
Completed Clinical Trials
Clinical Publications
Indications
Back
EPI in Cystic Fibrosis
Checkpoint Inhibitor Colitis
COVID-19 GI Infection
Investors
Back
Press Releases
Back
2021
2020
2019
2018
2017
2016
2015
2014
Events
Presentations
Regulatory Filings
Financial Statements
Stock Info
Analyst Coverage
Corporate Governance
Contact Us
News & Publications
Back
Press Releases
Media
Publications
Contact
Back
Contact Us
Subscribe
Home
Investors
Investor Relations
Stock Quote - AzurRx (NASDAQ: AZRX)
Menu
Press Releases
2021
2020
2019
2018
2017
2016
2015
2014
Events
Presentations
Regulatory Filings
Financial Statements
Stock Info
Analyst Coverage
Corporate Governance
Contact Us
Stock Quote - AzurRx (NASDAQ: AZRX)
*Delayed quote courtesy of Google.
Stock Chart
1 Month
3 Months
6 Months
1 Year
Recent Press Releases
Date
Title
15 Apr, 2021
AzurRx BioPharma CEO Issues Letter to Shareholders
13 Apr, 2021
AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis
06 Apr, 2021
AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections